Pharmaceuticals

FDA Approval of CAR T-Cell Therapy by Bristol Myers Squibb Driving Innovation in the Blood Cancer Drugs Market

March 18, 2026March 18, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Blood Cancer Drugs Market Projected To Become By 2030 Based On Its 2026 Valuation?

The blood cancer drugs market size has seen substantial growth in recent years. It is projected to increase from $79.6 billion in 2025 to $84.59 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.3%. This historical expansion can be linked to factors like the rising prevalence of leukemia and lymphoma, the persistent use of chemotherapy, the establishment of more oncology hospitals, the accessibility of monoclonal antibodies, and enhancements in diagnostic capabilities.

The blood cancer drugs market is anticipated to show significant expansion in the coming years. This market is projected to reach $111.86 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.2%. The growth during the forecast period is attributed to the rise of precision oncology, increasing adoption of stem cell therapies, innovations in biologics, escalating healthcare expenditure, and the expansion of cancer screening programs. Key trends expected in the forecast period include the growing uptake of targeted blood cancer therapies, the expanded use of immunotherapy in hematologic malignancies, the proliferation of combination treatment approaches, a heightened focus on personalized cancer treatment, and improved survival outcomes for blood cancer patients.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2587&type=smp

Which Market Drivers Are Supporting The Expansion Of The Blood Cancer Drugs Market?

The rising global occurrence of blood cancer cases is anticipated to stimulate the expansion of the blood cancer drug market moving forward. Blood cancer refers to a category of severe medical conditions, including leukemia, lymphoma, and myeloma, which affect the blood and bone marrow, demanding prolonged, specialized medical interventions such as chemotherapy, immunotherapy, precision medicines, and stem cell transplantation. This upward trend in disease frequency can be attributed to elements like an aging populace, genetic changes, exposure to environmental factors, and lifestyle-related risks. The growing count of blood cancer diagnoses is leading to an amplified demand for innovative blood cancer drugs that promise enhanced survival rates, reduced side effects, better quality of life for patients, and tailored therapeutic approaches. Illustratively, in October 2025, Blood Cancer United, a US-based blood cancer information and advocacy group, projected that approximately 66,890 individuals would be diagnosed with leukemia, with about 475,323 people in the United States either living with or having achieved remission from the disease, and an estimated 23,540 deaths expected from leukemia in 2025. Therefore, the increasing worldwide prevalence of blood cancer cases is a significant catalyst for the growth of the blood cancer drug market.

What Segment Groups Are Identified Within The Blood Cancer Drugs Market?

The blood cancer drugs market covered in this report is segmented –

1) By Blood Cancer Type: Leukemia, Lymphoma

2) By Drugs: Rituxan Or Mabthera (Rituximab), Gleevec Or Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), Other Drugs

3) By Treatment Approaches: Chemotherapeutic, MAbs/Targeted Therapies, Immunotherapeutic

Subsegments:

1) By Leukemia: Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Other Types of Leukemia

2) By Lymphoma: Hodgkin Lymphoma, Non-Hodgkin Lymphoma (NHL), Burkitt Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Other Types of Lymphoma

What Trends Are Advancing Progress In The Blood Cancer Drugs Market?

Leading companies within the blood cancer drugs market are concentrating on developing new medications and actively seeking FDA approval to secure a competitive edge. FDA approval for drugs denotes the official authorization granted by the United States Food and Drug Administration, permitting a pharmaceutical product to be legally commercialized and distributed in the United States. For example, in March 2024, Bristol Myers Squibb, a US-based pharmaceutical company, obtained FDA approval for its sole CAR T-cell therapy designed for adults experiencing relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This accelerated approval enables its use in patients who have previously undergone at least two treatments, including a Bruton tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor. According to the TRANSCEND CLL 004 trial, Breyanzi showed a 20% complete response rate and a median duration of response of 35.3 months among individuals who responded.

Which Companies Hold Significant Positions In The Blood Cancer Drugs Market?

Major companies operating in the blood cancer drugs market are Amgen Inc., AstraZeneca PLC, Bayer AG, Eli Lilly and Company Inc., Johnson & Johnson, Novartis AG, Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Astellas Pharma Inc., Merck & Co. Inc., Gilead Sciences Inc., Sanofi S.A., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Kyowa Kirin Co. Ltd., Menarini Group, Millennium Pharmaceuticals Inc., Mundipharma International Limited, Mylan N.V., Ono Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Pharmacyclics LLC, Seattle Genetics Inc., Servier Laboratories, Shire plc, Spectrum Pharmaceuticals Inc., Taiho Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Tolero Pharmaceuticals Inc., UCB S.A.

Read the full blood cancer drugs market report here:

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

How Is The Blood Cancer Drugs Market Distributed Across Key Geographic Regions?

North America was the largest region in the blood cancer drugs market in 2025. Middle East is expected to be the fastest-growing region in the blood cancer drugs market during the forecast period. The regions covered in the blood cancer drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Blood Cancer Drugs Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2587&type=smp

Browse Through More Reports Similar to the Global Blood Cancer Drugs Market 2026, By The Business Research Company

Blood Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Oncology Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Kidney Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/kidney-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795